MORGAN STANLEY PLC/CALL/MEDTRONIC/140/0.1/20.06.25 Stock

Warrant

DE000ME6VDA6

Real-time Bid/Ask 08:13:23 2024-06-18 am EDT
0.071 EUR / 0.083 EUR -8.33% Intraday chart for MORGAN STANLEY PLC/CALL/MEDTRONIC/140/0.1/20.06.25
Current month+147.06%
1 month+100.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-18 0.072 -14.29%
24-06-17 0.084 +31.25%
24-06-14 0.064 0.00%
24-06-13 0.064 +56.10%
24-06-12 0.041 +2.50%

Delayed Quote Börse Stuttgart

Last update June 18, 2024 at 05:59 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer Morgan Stanley
WKN ME6VDA
ISINDE000ME6VDA6
Date issued 2024-01-12
Strike 140 $
Maturity 2025-06-20 (367 Days)
Parity 10 : 1
Emission price 0.08
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.092
Lowest since issue 0.024
Spread 0.011
Spread %13.25%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
79.95 USD
Average target price
94.07 USD
Spread / Average Target
+17.66%
Consensus